International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPatterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma
Introduction
Glioblastoma is a high-grade primary brain malignancy with a dismal prognosis. The median survival is on the order of 6 to 18 months, with nearly all patients eventually succumbing to their disease. The standard treatment for newly diagnosed glioblastoma includes a multimodality approach with surgery, radiation therapy (1), and chemotherapy (2). A recent European and Canadian randomized study demonstrated a survival benefit with the addition of concurrent and adjuvant temozolomide (3).
Although autopsy (4) and stereotactic biopsy (5) studies demonstrate widespread microscopic infiltration within the brain, local recurrence predominates with this disease, most often within 2 cm of the original tumor volume after whole brain radiation 6, 7, 8 or more conformal radiation (9, 10, 11, 12, 13, 14, 15, 16, 17). Conformal radiation to the enhancing tumor and peritumoral edema has become standard. Generally, doses of ∼60 Gy are prescribed 1, 18. Dose escalation to 90 Gy 19, 20 or the addition of stereotactic radiosurgery (SRS) boost (21) may reduce failures within the high-dose volumes, although recurrence then tend to occur just outside the high-dose region. Several studies have analyzed recurrences after implant boost 22, 23, 24, 25, though the data on how implants affect patterns of recurrence is conflicting, with at least one study demonstrating a preponderance of out-of-field recurrences (24).
We retrospectively reviewed the patterns of recurrence of patients treated with radiation therapy concurrently with temozolomide chemotherapy. Temozolomide acts a radiation sensitizer, potentially augmenting the local control of glioblastoma. It is not known whether patients are then more susceptible to developing recurrences outside of the radiation field as a result of this improved tumor control and longer survival. Conversely, temozolomide, by virtue of its systemic activity, may help to prevent the development of new lesions remote from the primary tumor. We hypothesized that the longer survival and better tumor control of glioblastoma in patients treated with temozolomide-based chemoradiation may affect the patterns of recurrence, and sought to better characterize the patterns of recurrence in these patients.
Section snippets
Methods and Materials
Since 2005, patients treated for glioblastoma at the University of Rochester have been routinely treated, as standard therapy, with temozolomide concurrent with radiation. The medical records of patients with glioblastoma diagnosed between March 2005 and March 2008 were reviewed. The study was approved by the University of Rochester Research Subjects Review Board.
Patients underwent biopsy or resection before receiving radiation, with all patients having pathologic confirmation of glioblastoma.
Results
A total of 116 patients with glioblastoma were seen at the University of Rochester from March 2005 to March 2008. Of these, 54 were eligible for this study. Reasons for exclusion of the other 62 were as follows (with 11 having >1 reason): 26 received twice-daily radiation therapy per a University of Rochester protocol, 2 declined any adjuvant therapy, 8 received palliative radiation fractionation, 14 were not offered concurrent temozolomide, 13 had multifocal disease, 11 died before completing
Discussion
The present study is one of the first 17, 31, 32 to examine recurrence patterns after temozolomide-based chemotherapy. We hypothesized that temozolomide, by virtue of its radiation sensitization, may augment the effective radiation dose and therefore may affect patterns of recurrence. The systemic activity of temozolomide may also affect recurrence patterns. However, in a recent European Organization for Research and Treatment of Cancer study in which first recurrences were mapped using
References (39)
- et al.
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Int J Radiat Oncol Biol Phys
(1979) - et al.
Radiation therapy treatment planning in supratentorial glioblastoma multiforme: An analysis based on post mortem topographic anatomy with CT correlations
Int J Radiat Oncol Biol Phys
(1989) - et al.
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma
Int J Radiat Oncol Biol Phys
(1989) - et al.
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas
Radiother Oncol
(1991) - et al.
Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment
Int J Radiat Oncol Biol Phys
(1992) - et al.
Malignant glioma: Patterns of failure following individually tailored limited volume irradiation
Radiother Oncol
(1994) - et al.
3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation
Radiother Oncol
(1999) - et al.
Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study
Int J Radiat Oncol Biol Phys
(1999) - et al.
Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings
Int J Radiat Oncol Biol Phys
(2007) - et al.
High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme
Int J Radiat Oncol Biol Phys
(1998)
Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage
Int J Radiat Oncol Biol Phys
Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas
Int J Radiat Oncol Biol Phys
Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants
Int J Radiat Oncol Biol Phys
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost
Int J Radiat Oncol Biol Phys
Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy
Int J Radiat Oncol Biol Phys
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Lancet Oncol
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme
Int J Radiat Oncol Biol Phys
Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors
Int J Radiat Oncol Biol Phys
Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials
Lancet
Cited by (122)
Photodynamic therapy using talaporfin sodium for sub-totally resectable malignant glioma
2024, Photodiagnosis and Photodynamic TherapyDosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients
2023, Radiotherapy and OncologyLong-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma
2021, Journal of Clinical NeuroscienceCitation Excerpt :The cohort included all consecutive cases treated by the BCNU wafers in the temozolomide era and received different treatments after recurrences; therefore, multiple factors may affect the survival and recurrence pattern. Indeed, several retrospective studies showed different survival and recurrence patterns based on MR imaging or the radiation field [5,6,33,38]. We showed that glioblastoma with non-local recurrence presented shorter OS, but non-local recurrence itself is a poor prognostic factor [39] without the BCNU wafers implantation.
Conflict of interest: none.